This is also reflected in vivo, where increased tissue immunoreactivity for ET-1 has been demonstrated in numerous cancer types, including ovarian, hepatocellular and breast tumours (Bagnato et al, 1999; Yamashita et al, 1991; Suzuki et al, 1998). The gene discussed is EDN1; the disease is cancer.